Sientra® to Release Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019
March 04 2019 - 4:44PM
Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company
(“Sientra or the “Company”), announced today that the Company will
release its fourth quarter and full year 2018 financial results on
Tuesday, March 12, 2019 after market close.
Sientra will hold a conference call on Tuesday,
March 12, 2019 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results.
A press release disclosing the Company's financial results will be
distributed at approximately 1:00 p.m. PT/4:00 p.m. ET that same
day.
The dial-in numbers are (844) 464-3933 for
domestic callers and (765) 507-2612 for international callers. The
conference ID is 6538838. A live webcast of the conference
call will be available on the Investor Relations section of the
Company's website at www.sientra.com.
A replay of the call will be available starting
on March 12, 2019 at 4:30 p.m. PT/7:30 p.m. ET, through March 19,
2019 at 8:59 p.m. PT/11:59 p.m. ET. To access the replay,
dial (855) 859-2056 for domestic callers and (404) 537-3406 for
international callers and use the replay conference ID 6538838. The
webcast will be available on the Investor Relations section of the
Company’s website for 30 days following the completion of the call.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a
diversified global medical aesthetics company and a leading partner
to aesthetic physicians. The Company offers a suite of products
designed to make a difference in patients' lives by enhancing their
body image, growing their self-esteem, and restoring their
confidence. Sientra has developed a broad portfolio of products
with technologically differentiated characteristics, supported by
independent laboratory testing and strong clinical trial
outcomes. The Company’s Breast Products Segment
includes its OPUS™ breast implants, the first fifth generation
breast implants approved by the FDA for sale in the United States,
its ground-breaking Allox2® breast tissue expander with patented
dual-port and integral drain technology, and BIOCORNEUM® the
#1 performing, preferred and recommended scar gel of plastic
surgeons(*). The Company’s miraDry Segment, comprises its
miraDry® system, which is approved for sale in over 40
international markets, and is the only non-invasive FDA-cleared
device for the permanent reduction of underarm sweat, odor and hair
of all colors.____________________(*) Data on file
Investor Contact:Neil
Bhalodkar805-679-8845ir@sientra.com
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Sep 2023 to Sep 2024